Conditions: Diabetes Mellitus, Type 2 Kidney Failure, Chronic Hyperlipidemia
Keywords: Diabetes Mellitus, Type 2 Kidney Failure, Chronic Hyperlipidemia Randomized Controlled Trials
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further development of kidney damage.

Detailed description:
Diabetic nephropathy is the leading cause of end stage kidney disease in the United States. Patients with chronic kidney disease have a markedly increased risk of death from cardiovascular disease, and traditional risk factors such as hyperlipidemia have been shown to be of critical importance. Almost 90% of patients with diabetes and chronic kidney disease have lipid abnormalities. Here, we investigate whether Niaspan, taken in addition to lipid-lowering drugs referred to as "statins", will decrease LDL cholesterol and increase LDL particle size, increase HDL, reduce proteinuria, and reduce the speed of loss of renal function.

Arms:
arm 1: Extended release niacin 1500-2000 mg daily versus placebo comparator arm 2: Placebo tablets

Interventions: intervention 1: Extended release niacin intervention 2: Placebo
Intervention descriptions: intervention 1: Extended release niacin 1500-2000mg once daily intervention 2: Placebo tablets

Protocol document: